Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

Discover why Hims & Hers faces steep corrections amid GLP-1 headwinds and valuation concerns, despite promising FY2024 growth ...

Hims & Hers Health ( HIMS -15.90%) has been a top healthcare stock to own over the past five years, soaring by around 350% ...

Share on Pinterest Hims and Roman are telemedicine brands that provide quick shipping and discreet delivery for treatments for erectile dysfunction (ED), premature ejaculation (PE), and other ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Shares of direct-to-consumer healthcare platform Hims & Hers (HIMS) raced 60% higher over the past week after a successful Super Bowl ad, despite lingering disappointment over its earnings report.

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers (HIMS) stock is sinking 20% today after Eli Lilly (LLY) unveiled significantly cheaper versions of its popular weight-loss drugs today. Additionally, the FDA last week hindered the ...

Hims and Roman are telehealth companies that sell prescription and nonprescription products to treat erectile dysfunction (ED), hair loss, and premature ejaculation (PE). Both ED and hair loss can ...

In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against the other skincare stocks. According to NielsenIQ, the global beauty market is expected to ...

HIMS stock is going bananas with the stock up nearly 200% YTD at one point. However, the stock sold off due to the FDA's announcement that semaglutide will be taken off the shortage list. While ...